An Alternative Domain Containing a Leucine-rich Sequence Regulates Nuclear Cytoplasmic Localization of Protein 4.1R*

Carlos M. LuqueDagger §, Carmen M. Pérez-FerreiroDagger , Alicia Pérez-GonzálezDagger , Ludwig Englmeier||**, Maria D. Koffa||, and Isabel CorreasDagger DaggerDagger

From the Dagger  Departamento de Biología Molecular, Centro de Biología Molecular "Severo Ochoa" (Consejo Superior de Investigaciones Científicas/Universidad Autónoma de Madrid), Universidad Autónoma de Madrid, E-28049 Madrid, Spain and the || European Molecular Biology Laboratory, Gene Expression Programme, D-69117 Heidelberg, Germany

Received for publication, February 14, 2002, and in revised form, November 7, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In red blood cells, protein 4.1 (4.1R) is an 80-kDa protein that stabilizes the spectrin-actin network and anchors it to the plasma membrane. The picture is more complex in nucleated cells, in which many 4.1R isoforms, varying in size and intracellular location, have been identified. To contribute to the characterization of signals involved in differential intracellular localization of 4.1R, we have analyzed the role the exon 5-encoded sequence plays in 4.1R distribution. We show that exon 5 encodes a leucine-rich sequence that shares key features with nuclear export signals (NESs). This sequence adopts the topology employed for NESs of other proteins and conserves two hydrophobic residues that are shown to be critical for NES function. A 4.1R isoform expressing the leucine-rich sequence binds to the export receptor CRM1 in a RanGTP-dependent fashion, whereas this does not occur in a mutant whose two conserved hydrophobic residues are substituted. These two residues are also essential for 4.1R intracellular distribution, because the 4.1R protein containing the leucine-rich sequence localizes in the cytoplasm, whereas the mutant protein predominantly accumulates in the nucleus. We hypothesize that the leucine-rich sequence in 4.1R controls distribution and concomitantly function of a specific set of 4.1R isoforms.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Red blood cell protein 4.1, 4.1R, or 4.1R80 was identified in human erythrocytes as an 80-kDa multifunctional protein that stabilizes the spectrin-actin network. Protein 4.1R anchors this network to the overlying lipid bilayer through interactions with cytoplasmic domains of transmembrane proteins (1). For the maintenance of normal erythrocyte morphology and the mechanical strength of the membrane, the formation of the spectrin-actin-4.1R ternary complex is essential; alterations in the spectrin-actin-binding site of 4.1R, located at the C-terminal region of the molecule (2-5) are associated with congenital hemolytic anemias (6).

In nucleated cells, multiple isoforms of 4.1R are expressed as a result of extensive alternative splicing of the 4.1R pre-mRNA (7-10). This event is cell- and tissue-specific and also dependent on growth and differentiation stages of the cell (10-13). Immunological studies have detected 4.1R epitopes at different intracellular sites (14-20). Concomitantly, the association of 4.1R with proteins localized at different intracellular sites have been reported (21-27), thus suggesting that 4.1R may be involved in many processes in nucleated cells. A possible role for 4.1R in organizing the nuclear and microtubule architecture and the mitotic spindle poles has been suggested. 4.1R is known to interact with nuclear components of the splicing machinery (19, 22), pICln (28), a regulator of a chloride channel recently shown also to associate with spliceosomal proteins (29), interphase microtubules (30), a novel centrosomal protein termed CPAP (31), and the nuclear mitotic apparatus protein (32). Transfection studies using 4.1R cDNAs isolated from different sources have allowed the identification of specific nuclear isoforms of 4.1R (32-35) and the signals involved in 4.1R nuclear targeting (33, 34, 36) and the abrogation of its nuclear accumulation (34, 37).

Nuclear transport in eukaryotic cells is triggered by specific transport signals that are recognized by soluble receptors that interact with the nuclear pore complexes. Nuclear import is mediated by nuclear localization signals present in nuclear proteins. In the case of classical basic nuclear localization signals, this process involves the importin alpha  and importin beta  proteins, whose function is regulated by Ran GTPase (38, 39). Like import, nuclear export is mediated by specific signals known as nuclear export signals (NESs).1 There are two relatively well defined exportins that transport proteins: CAS and CRM1. These receptors associate in the nucleus with their export substrates in the presence of Ran-GTP forming trimeric export complexes that are then transferred to the cytoplasm (40). Human CRM1 binds leucine-rich NESs found in different proteins such as Rev, mitogen-activated protein kinase kinase 1, cAMP-dependent protein kinase inhibitor, and cyclin B (41-44).

In our previous studies, which focused on the identification of signals involved in differential intracellular localization of proteins 4.1R (33, 34, 37), we showed that a constitutive region of the 4.1R molecule, one that is therefore present in all 4.1R isoforms and is thus designated as the "core region," was responsible for nuclear targeting of 4.1R (34). Because 4.1R isoforms expressing exon 5 are predominantly localized in the cytoplasm (34), in this study we have aimed to identify the amino acid sequence that is responsible for this effect. We show here that exon 5 encodes a leucine-rich sequence resembling a NES. This sequence and, more specifically, two leucine residues that are also conserved in NESs are necessary for 4.1R cytoplasmic localization and for 4.1R binding to the export receptor CRM1.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture and Transfection-- COS-7 cells were used for transient cDNA expression, immunofluorescence, and biochemical analyses. The cells were grown as described (33). Transient transfections were performed by electroporation using the Electro Cell Manipulator 600 (BTX, San Diego, CA). The cells were always processed 48 h after transfection. For each cDNA construct tested, more than 300 cells from at least five independent replicates were counted.

cDNA Cloning, Composite cDNA Constructs, and Mutagenesis-- 4.1R80Delta 16 and 4.1R80Delta 5,16 cDNAs were cloned and tagged as described (34). 4.1R80Delta 16-GFP and 4.1R60Delta 16,18-GFP were constructed by PCR using pSRalpha 4.1R80Delta 16 and pSRalpha 4.1R60Delta 16,18 as templates (34), respectively, and appropriate sense and antisense primers complementary to both ends of their respective open reading frames. E5-GFP was constructed by PCR using pSRalpha 4.1R80Delta 16 as a template and sense and antisense primers complementary to both ends of 4.1R exon 5 coding sequence. The PCR-amplified sequences were cloned into the vector pcDNA3.1/CT-GFP-TOPO® (Invitrogen) following the manufacturer's instructions. GST-4.1R80Delta 16 was prepared as described (30). The constructs zz-CRM1, GST-RevNES, GST-M10, and RanGTP were prepared as reported (45).

The mutated constructs 4.1R80Delta 16NESmut, 4.1R80Delta 16LEEDYmut, and GST-4.1R80Delta 16NESmut were obtained using the QuikChange site-directed mutagenesis kit (Stratagene). The reactions were performed following the manufacturer's instructions, using pSRalpha 4.1R80Delta 16 or pGEX 4.1R80Delta 16 (30) as a template and the appropriate pair of oligonucleotides covering both strands of the region of interest. In 4.1R80Delta 16NESmut and GST-4.1R80Delta 16NESmut, L34NL was mutated to ANQ. In 4.1R80Delta 16LEEDYmut, L37EEDY was mutated to SRAGN. The amino acids were numbered according to the erythroid 4.1R sequence (10), GenBankTM accession number M61733.

Antibodies-- Anti-c-Myc (9E10) monoclonal antibody (46) was obtained from the American Type Culture Collection. Goat anti-mouse IgG secondary antibodies conjugated with horseradish peroxidase or fluorescein isothiocyanate were obtained from Southern Biotechnology Associates, Inc. (Birmingham, AL). Anti-GST monoclonal antibody was purchased from GeneTex (San Antonio, TX).

Immunofluorescence Microscopy-- Cells grown on glass coverslips were fixed, permeabilized, and blocked as described (33). The cells were incubated with the appropriate antibodies and processed as reported (16). The preparations were examined using a Zeiss epifluorescence microscope. Controls to assess the specificity and lack of cross-labeling included incubations with nonimmune rabbit serum and control monoclonal antibodies or omission of either of the primary antibodies.

Protein Expression and Western Blot Analysis-- For binding assays, GST fusion proteins were expressed and purified using standard procedures (47). To verify their size, as well as those of the proteins expressed in transfection experiments using COS-7 cells, total protein extracts were obtained, and the protein fractions were analyzed by SDS-PAGE (48) and Western blot. The membranes were processed and developed as described elsewhere (16).

Solution Binding Assays-- For binding assays with zz-tagged CRM1 (45, 49), 10 µg of zz-CRM1/binding reaction were incubated with IgG-Sepharose beads for 30 min at 4 °C in 100 µl of binding buffer (100 mM potassium acetate, 30 mM HEPES-KOH, pH 7.5, 2 mM magnesium acetate, and 0.001% Triton X-100). The beads were then recovered by gentle centrifugation and washed with binding buffer. The beads were subsequently incubated with candidate proteins in a final volume of 100 µl for 60 min at 4 °C. The beads were recovered by gentle centrifugation and washed four times with 1 ml of binding buffer. The bound proteins were eluted by the addition of 1 ml of 1 M MgCl2, and the eluted proteins were precipitated with isopropanol. The protein pellets were resuspended in Laemmli (48) sample buffer and analyzed by SDS-PAGE and Western blot.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Exon 5-encoded Sequence Alters the Subcellular Localization of Nuclear GFP-- To study the role that the exon 5-encoded sequence plays in 4.1R intracellular distribution, we prepared different cDNA fusion constructs in which the sequence coding for GFP was appended at the 3' end of 4.1R coding sequences (Fig. 1). Transfection experiments were performed in COS-7 cells and the distribution patterns of the expressed proteins were analyzed 48 h post-transfection by fluorescence microscopy. Cells expressing only GFP had intense nuclear staining with some fluorescence also detected in the cytoplasm (Fig. 2A and Table I). Cells expressing a fusion protein containing the complete amino acid sequence of a nuclear 4.1R isoform that lacked expression of exon 5 (4.1R60Delta 16,18-GFP) also showed predominant nuclear staining (Fig. 2B and Table I). By contrast, cells expressing a 4.1R isoform containing the sequence encoded by exon 5 (4.1R80Delta 16-GFP) presented predominantly cytoplasmic staining (Fig. 2C and Table I). Consistently, appending the 35 amino acids encoded by exon 5 to GFP (E5-GFP) also resulted in an increase in the number of cells showing cytoplasmic fluorescence (Fig. 2D and Table I).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 1.   Scheme of the exon map for the 4.1R protein and the cDNA constructs used in this study. A, schematic representation for the protein 4.1R. The exons are coded as follows: striped, alternative; white, constitutive; black, noncoding. The number of each individual exon is represented. Three translation initiation sites at exons 2' (ATG-1), 4 (ATG-2), and 8 (ATG-3) are indicated, as well as the stop codon (TGA) at exon 21. These data have been taken from Refs. 10, 12, 13, 34, 35, and 65. B, exon composition of the 4.1R cDNAs and GFP and GST fusion proteins used in this study. The nucleotide sequence encoding the c-Myc-epitope tag (myc) was added at the 3' end of cloned cDNAs. GFP protein is expressed at the C terminus, whereas GST is at the N terminus of the expressed 4.1R chimeras. Mutations introduced in different 4.1R cDNAs and constructs are indicated. In 4.1R80Delta 16NESmut and GST-4.1R80Delta 16NESmut, residues Leu34 and Leu36 within the leucine-rich sequence were replaced by Ala and Gln, respectively. In 4.1R80Delta 16LEEDYmut, the sequence L37EEDY was replaced by SRAGN (see "Experimental Procedures" for details).


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of the exon 5-encoded sequence of 4.1R on the subcellular localization of GFP. COS-7 cells were transfected with GFP (A), 4.1R60Delta 16,18-GFP (B), 4.1R80Delta 16-GFP (C), or E5-GFP (D) cDNAs and examined by fluorescence microscopy 48 h after transfection. Green represents fluorescence of GFP; blue represents nuclear staining with 4'-6'-diamidino-2-phenylindole.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Subcellular distribution of various proteins used in this study and expressed in COS-7 cells
The different cDNAs were prepared and transfected as described under "Experimental Procedures." The distribution pattern of each protein was assayed in approx 300 cells from five independent transfection experiments. The percentages of transfected cells showing immunofluorescence staining only in the cytoplasm (c), predominantly in the cytoplasm (c > n), at similar levels in the cytoplasm and the nucleus (c = n), predominantly in the nucleus (n > c), and only in the nucleus (n) were estimated 48 h after transfection.

A Leucine-rich Sequence Resembling a NES in 4.1R Isoforms Expressing the Alternative Exon 5-- NES sequences are short sequence motifs that are necessary and sufficient to mediate the nuclear export of large proteins (38, 39, 50). Important for their function is a characteristic spacing of hydrophobic residues, mainly leucine or isoleucine (38, 39). Analysis of the amino acid sequence coded by exon 5 allowed the identification of a hydrophobic region, L26LKRVCEHLNLL, which is significantly similar to leucine-rich NES sequences (Fig. 3A). The key hydrophobic residues shown to be important for NES function in other proteins (51, 52) are also found in the putative NES in 4.1R and correspond to Leu34 and Leu36 (numbered as in the erythroid 4.1R sequence reported in Ref. 10). The crystal structure of the N-terminal 30-kDa domain of erythroid 4.1R comprising exon-5-encoded sequence has been determined (53). From the tertiary structure it may be inferred that the 4.1R hydrophobic sequence, L26LKRVCEHLNLL, adopts an alpha -helix conformation (Fig. 3D). Leu36 is exposed on one side of the alpha -helix, whereas Leu34 and the hydrophobic residues Leu26 and Val30 are exposed on the opposite side (Fig. 3B). A similar topology has been described for other NES (50, 54, 55), such as that of protein p53, in which Leu350 is located on one side of the alpha -helix, whereas Leu348 and the hydrophobic residues Met340 and Leu344 appear on the opposite side (Fig. 3C).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 3.   The leucine-rich sequence encoded by exon 5 of 4.1R resembles NESs characterized in a variety of proteins. A, alignment of the leucine-rich sequence of 4.1R with NES sequences of mitogen-activated protein kinase kinase (MAPKK), zyxin, RevHIV, p53, actin, and cAMP-dependent protein kinase inhibitor, alpha  form (PKIalpha ). The conserved hydrophobic amino acids are blue; the two most highly conserved residues crucial to the proper function of NES are marked with two dots. B, three-dimensional structure of the leucine-rich sequence present in protein 4.1R. Amino acids are color-coded as follows: yellow for hydrophobic, red for acidic, blue for basic, and green for polar residues. C, three-dimensional structure of the NES present in p53 protein. D, three-dimensional structure of the FERM domain of 4.1R (53) showing the position of the leucine-rich sequence in an exposed alpha -helix. The two conserved residues, Leu34 and Leu36, are shown. E, predicted three-dimensional structure of the mutated FERM domain of 4.1R80Delta 16NESmut showing the position of the two mutated residues, Ala34 and Gln36. A was prepared using the ClustalX alignment program (66). B-E were modeled using the Swiss PDB Viewer program (67), based on the crystallographic coordinates of the 4.1R80 FERM (53) and p53 tetramerization (55) domains deposited in the Protein Data Bank with accession numbers 1GG3 and 1AE1, respectively. In E, the FOLD-X program (56), available at fold-x.embl-heidelberg.de, was used to predict the coordinates of the mutated FERM domain. Note that the overall structure of the domain is not altered and that the alpha -helix comprising the mutated leucine-rich sequence remains exposed to the solvent.

Mutation of Two Essential Residues within the Leucine-rich Sequence Alters the Cytoplasmic Localization of Protein 4.1R-- Mutation of two critical hydrophobic amino acids within NES sequences has been shown to affect the function of NES in many proteins (51, 52). We next investigated whether mutations of the two conserved and presumably critical hydrophobic amino acids within the 4.1R leucine-rich sequence also affect 4.1R subcellular distribution. COS-7 cells were transfected with either a cDNA coding the wild-type protein for the expression of the leucine-rich sequence (4.1R80Delta 16) or a cDNA encoding a protein with Leu34 and Leu36 replaced by Ala34 and Gln36 within the leucine-rich sequence (4.1R80Delta 16NESmut). The subcellular distribution of the expressed proteins, tagged with c-Myc sequences at the C terminus, was determined by staining with antibody 9E10.

Wild-type 4.1R80Delta 16 protein had a predominantly cytoplasmic distribution (Fig. 4A and Table I) with a small percentage of the transfected cells containing the expressed protein in the nucleus and cytoplasm (Table I). By contrast, protein 4.1R80Delta 16NESmut was predominantly distributed in the nucleus (Fig. 4B and Table I). An explanation for the results obtained for the mutated 4.1R protein could be that it is first directed to the nucleus via its core region (34) and that once there it cannot be exported to the cytoplasm because the two mutated hydrophobic amino acids, Leu34 and Leu36, are essential for nuclear export. The predicted folding of the mutant was determined using as template the crystallographic coordinates of the 4.1R80 FERM domain (53) deposited in the Protein Data Bank (accession number 1GG3) and the FOLD-X computer algorithm (56) (Fig. 3E). Substitution of Leu34 and Leu36 by Ala34 and Gln36 is not predicted to cause perturbation of folding and is slightly favorable to protein stability (the free energy of folding is 52.32 kcal·mol-1 for the wild type versus 52.14 kcal·mol-1 for the mutant). It is very unlikely that the results described above for the mutant are due to perturbation of folding. Isoform 4.1R80Delta 5,16, which is similar to 4.1R80Delta 16 except for lacking exon 5-encoded sequences, also accumulates in the nucleus (Fig. 4C and Table I). All of these results indicate that although wild-type 4.1R80Delta 16 is found predominantly in the cytoplasm, either the mutation in the leucine-rich sequence or the deletion of exon 5 clearly resulted in the accumulation of the protein in the nucleus. Thus, the leucine-rich sequence and, more specifically, amino acids Leu34 and Leu36 play a pivotal role in 4.1R cytoplasmic distribution in COS-7 cells.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 4.   Two conserved leucine residues within the sequence L26LKRVCEHLNLL are involved in 4.1R cytoplasmic distribution. COS-7 cells were transfected with 4.1R80Delta 16 (A), 4.1R80Delta 16NESmut (B), 4.1R80Delta 5,16 (C), or 4.1R80Delta 16LEEDYmut (D) cDNAs, labeled with anti-c-Myc (9E10) antibody (green) and examined by epifluorescence microscopy 48 h after transfection. Blue represents nuclear staining with 4'-6'-diamidino-2-phenylindole.

The binding site of band 3 to 4.1R consists of the L37EEDY sequence that is adjacent to the NES (57). Mutation of L37EEDY to S37RAGN (protein 4.1R80Delta 16LEEDYmut), unlike 4.1R80Delta 16NESmut, did give rise to predominant cytoplasmic staining of 4.1R80Delta 16LEEDYmut (Fig. 4D and Table I). The capacity of protein 4.1R80Delta 16 to be exported from the nucleus was analyzed by injecting recombinant protein GST-4.1R80Delta 16 into Xenopus laevis oocyte nuclei and processing the samples as described (58). At 3 h post-injection, most of the protein GST-4.1R80Delta 16 was detected in the cytoplasmic fraction supporting nuclear export of 4.1R80Delta 16 (data not shown). The mutant protein GST-4.1R80Delta 16NESmut was also detected in the cytoplasmic fraction. This unexpected result suggests that 4.1R contains additional nuclear export signal(s) that appear(s) to be functional in the X. laevis oocyte system.

Protein 4.1R80Delta 16, but not 4.1R80Delta 16NESmut, Associates with the Nuclear Export Protein CRM1 in a RanGTP-dependent Manner-- Proteins containing a leucine-rich NES are recognized in the nucleus by the exportin CRM1 and form a trimeric complex with RanGTP, which is exported from the nucleus to the cytoplasm (40). We investigated whether 4.1R80Delta 16 associates with CRM1 in the RanGTP-dependent manner characteristic of export substrates. zz-tagged CRM1 was bound to IgG-Sepharose and incubated with the different substrates used in the binding assays. Bead-bound material was eluted from the column and processed as indicated under "Experimental Procedures." A functional export substrate containing the NES of Rev fused to the C terminus of GST (GST-RevNES) (45, 49) and an export-deficient control substrate containing a disrupted NES of Rev (GST-M10) were used as positive and negative controls, respectively. All of the binding assays were performed in the absence and presence of RanGTP. GST-RevNES bound efficiently to zz-CRM1, in a RanGTP-dependent manner (Fig. 5, compare lanes 1 and 2). Similarly, GST-4.1R80Delta 16 bound to CRM1 in a RanGTP-dependent manner (Fig. 5, compare lanes 5 and 6). By contrast, the export deficient control (GST-M10) and the 4.1R mutant in the leucine-rich sequence (GST-4.1R80Delta 16NESmut) did not bind to CRM1 even in the presence of RanGTP (Fig. 5, lanes 3 and 4 and lanes 7 and 8, respectively). The RanGTP-dependent binding of CRM1 to GST-4.1R80Delta 16 but not to GST-4.1R80Delta 16NESmut was more clearly revealed by Western blot analysis (Fig. 5, lanes 9-12).


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 5.   Protein 4.1R binds to CRM1 in a RanGTP-dependent manner. Proteins bound to CRM1 were isolated as indicated under "Experimental Procedures," analyzed by SDS-PAGE and Coomassie staining (lanes 1-8), or blotted to PVDF and detected by incubation with anti-GST antibody (lanes 9-12). GST-RevNES (RevNES) and GST-M10 (M10) were used as positive and negative controls, respectively. Note that GST-4.1R80Delta 16 protein (4.1R80Delta 16) binds zz-CRM1 in the presence, but not in the absence, of RanGTP, whereas the mutated GST-4.1R80Delta 16NESmut protein (4.1R80Delta 16NESmut) does not. Arrowheads mark the positions of GST-RevNES, RanGTP, and GST-4.1R80Delta 16.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In recent years, our view of strict compartmentalization of nuclear and non-nuclear components has been challenged as plasma membrane (59), tight junction (60), endocytic (61), and cytoskeletal (50) proteins have been described in the nucleus. Moreover, proteins interacting with 4.1R and with predominant extranuclear localization and function have recently been detected in the nucleus. One of these proteins is actin, which is a ubiquitous, essential cytoskeletal protein and is therefore like 4.1R80Delta 16 with a predominant cytoplasmic localization at steady state. Actin contains two functional NES that mediate its nuclear export in a CRM1-mediated manner. However, the physiological relevance of the shuttling of actin between the nucleus and cytoplasm is not known (50). ZO-1 interacts with 4.1R in cell tight junctions (24), and ZO-1 has been shown to accumulate in the nucleus in a cell density-dependent fashion (60). hCASK interacts with 4.1R, establishing a link between the extracellular matrix and the cortical actin cytoskeleton (21). It has been reported that hCASK directly enters the nucleus and thereby regulates gene expression (62). Conversely, a 4.1R-interacting protein, the nuclear splicing factor U2AF35 (22), has recently been shown to shuttle from the nucleus to the cytoplasm, but its role in the cytoplasm remains to be elucidated (63). This study shows that 4.1R isoforms expressing exon 5 contain a leucine-rich sequence that shares key features with NESs known to trigger the rapid, active delivery of proteins and RNA-protein complexes from the nucleus to the cytoplasm (39, 40, 64). Thus, the key hydrophobic residues important for NES function in other proteins are also found to be essential in 4.1R, and the topology adopted for the NES of proteins such as p53 (55) or actin (50) is similar to that adopted for 4.1R (53). Moreover, the leucine-rich sequence is required for 4.1R binding to CRM1 in a RanGTP-dependent fashion.

Our previous studies on signals involved in 4.1R differential intracellular localization showed that all 4.1R molecules have a common region, designated the core region, involved in their nuclear targeting (34). However, in this study we show that 4.1R isoforms expressing exon 5 contain a leucine-rich sequence that predominantly excludes them from the cell nuclei. A third signal comprising basic amino acids coded by the alternative exon 16 have also been involved in 4.1R nuclear targeting (33, 36). Finally, a fourth region mediating 4.1R intracellular localization is the 209-amino acid head piece (HP) of high molecular weight 4.1R135 isoforms that inhibits nuclear targeting of 4.1R (37). The complexity of signals and regions identified to date as being involved in 4.1R nuclear and cytoplasmic distribution and the hierarchical fashion in which they regulate the intracellular localization of 4.1R are summarized in Fig. 6A. Fig. 6B represents schematically possible models for the intracellular traffic experienced by different 4.1R isoforms. A first group of 4.1R80 isoforms containing the constitutive core region but lacking the alternative leucine-rich sequence is directed to the nucleus by a mechanism that has yet to be elucidated. This group would be comprised of the nuclear set of 4.1R isoforms (Fig. 6B, panel a). A second group of 4.1R80 isoforms contains the leucine-rich sequence, and these enter the nucleus via the core region and might bind to CRM1-RanGTP to be exported to the cytoplasm (Fig. 6B, panel b). A third group of 4.1R80 isoforms expresses exon 16, and they enter the nucleus by binding to human importin alpha 2, Rch1 (36) (Fig. 6B, panel c). Finally, a fourth group of 4.1R135 isoforms contains the HP domain that inhibits nuclear targeting of 4.1R (37). The HP domain might adopt a conformation masking the regions involved in 4.1R nuclear targeting. However, an association between the HP domain and a cytoplasmic partner could also account for this effect (Fig. 6B, panel d). Thus, there must be orchestrated regulatory mechanisms controlling the traffic of specific 4.1R isoforms to play distinct roles in different compartments.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 6.   Hierarchical organization of 4.1R targeting signals. A, the 4.1R cDNA has been divided into four regions represented by white boxes. Region 1, the 209-amino acid sequence, or HP, specific for 4.1R isoforms translated from ATG-1, which spans from ATG-1 to ATG-2; region 2, the sequence including the alternative exon 5 encoding the leucine-rich sequence (NES) and spanning from ATG-2 to ATG-3; region 3, the core region encompassing the sequence encoded from ATG-3 to the in-frame-ATG located at exon 17 (ATG-E17); region 4, the C-terminal region encoded from ATG-E17 to the 4.1R stop codon at exon 21 (TGA). The striped boxes indicate the alternative exons 5 and 16. Arrows show the sequences involved in 4.1R differential targeting. The directions of the arrows represent the predominant localization determined by the expression of every block of sequence: nuclear for the core region and for exon 16 (in the presence of exon 5) and cytoplasmic for exon 5 (in the absence of exon 16) and for the HP domain (33, 34, 36, 37). The hierarchical effect of these regions on 4.1R intracellular localization is as follows: the constitutive core region determines nuclear localization, which is blocked by expression of exon 5 (the leucine-rich sequence) and restored by the simultaneous expression of exons 5 and 16. Finally, the HP domain specific to 4.1R isoforms translated from ATG-1 is dominant over all the signals, being sufficient to abrogate nuclear entry (37). B, schematic representation of possible models indicating the intracellular traffic experimented by different sets of 4.1R isoforms (for explanation, see "Discussion").

We do not know the physiological role that 4.1R isoforms containing the leucine-rich sequence play in nucleated cells, and it is rather speculative, therefore, to propose possible cytoplasmic or nuclear roles. If the presence of 4.1R80Delta 16 in the cell nucleus has deleterious consequences for the cell, it is possible that the function of the leucine-rich sequence of 4.1R is to control the access of 4.1R to nuclear components. Alternatively, the sequence may be important for maintaining the cytoplasmic localization of a putative binding partner that would otherwise gain access to the nucleus to carry out specific functions. Lastly, 4.1R80Delta 16 may transit to the nucleus to deliver a nuclear component, either protein or RNA, to the cytoplasm. Protein 4.1R80Delta 16, and other 4.1R isoforms expressing exon 5, may be candidates for participation in the relay of information between the cytoplasm/plasma membrane and the nucleus. Investigation of the functions of 4.1R isoforms containing the leucine-rich sequence will provide new insights into this multifunctional protein.

    ACKNOWLEDGEMENTS

We thank Dr. Iain Mattaj for invaluable help and critical reading of the manuscript and Drs. Gareth Griffiths and Joost Schymkowitz for helpful suggestions (European Molecular Biology Laboratory, Heidelberg, Germany). We also acknowledge Dr. Scott Kuersten for generous help and Drs. Rainer Saffrich and Wilhelm Ansorge for hosting Dr. Luque in a short term visit to the European Molecular Biology Laboratory (Heidelberg, Germany). We are indebted to Dr. Miguel A. Alonso (Centro de Biología Molecular Severo Ochoa, Madrid, Spain) for helpful discussions.

    FOOTNOTES

* This work was supported by Grant BMC202-00978 from the Ministerio de Ciencia y Tecnología (Spain) and Grant 08.3/0004.1/99 from the Comunidad de Madrid (Spain). Institutional financial support was received from the Fundación Ramón Areces, Spain.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Recipient of a fellowship from the European Advanced Light Microscopy Facility at European Molecular Biology Laboratory in Heidelberg, Germany. Postdoctoral fellow of the Comunidad Autónoma de Madrid. Present address: European Molecular Biology Laboratory, Developmental Biology Programme, D-69117 Heidelberg, Germany.

Postgraduate fellow of the Ministerio de Educación, Ciencia y Cultura, Spain.

** Present address: Bardehle et al., Patent Attorneys, Possartstrasse 18, D-81679 Munich, Germany.

Dagger Dagger To whom correspondence should be addressed. Fax: 34-91-397-8087; E-mail: icorreas@cbm.uam.es.

Published, JBC Papers in Press, November 9, 2002, DOI 10.1074/jbc.M201521200

    ABBREVIATIONS

The abbreviations used are: NES, nuclear export signal; GST, glutathione S-transferase; HP, head piece domain of 4.1R; GFP, green fluorescent protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Conboy, J. G. (1993) Semin. Hematol. 30, 58-73[Medline] [Order article via Infotrieve]
2. Correas, I., Speicher, D. W., and Marchesi, V. T. (1986) J. Biol. Chem. 261, 13362-13366[Abstract/Free Full Text]
3. Correas, I., Leto, T. L., Speicher, D. W., and Marchesi, V. T. (1986) J. Biol. Chem. 261, 3310-3315[Abstract/Free Full Text]
4. Horne, W. C., Huang, S. C., Becker, P. S., Tang, T. K., and Benz, E. J., Jr. (1993) Blood 82, 2558-2563[Abstract]
5. Schischmanoff, P. O., Winardi, R., Discher, D. E., Parra, M. K., Bicknese, S. E., Witkowska, H. E., Conboy, J. G., and Mohandas, N. (1995) J. Biol. Chem. 270, 21243-21250[Abstract/Free Full Text]
6. Delaunay, J. (1995) Crit. Rev. Oncol. Hematol. 19, 79-110[CrossRef][Medline] [Order article via Infotrieve]
7. Tang, T. K., Leto, T. L., Correas, I., Alonso, M. A., Marchesi, V. T., and Benz, E. J., Jr. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 3713-3717[Abstract]
8. Tang, T. K., Qin, Z., Leto, T., Marchesi, V. T., and Benz, E. J., Jr. (1990) J. Cell Biol. 110, 617-624[Abstract]
9. Conboy, J. G., Chan, J., Mohandas, N., and Kan, Y. W. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 9062-9065[Abstract]
10. Conboy, J. G., Chan, J. Y., Chasis, J. A., Kan, Y. W., and Mohandas, N. (1991) J. Biol. Chem. 266, 8273-8280[Abstract/Free Full Text]
11. Chasis, J. A., Coulombel, L., Conboy, J., McGee, S., Andrews, K., Kan, Y. W., and Mohandas, N. (1993) J. Clin. Invest. 91, 329-338[Medline] [Order article via Infotrieve]
12. Baklouti, F., Huang, S. C., Vulliamy, T. J., Delaunay, J., and Benz, E. J., Jr. (1997) Genomics 39, 289-302[CrossRef][Medline] [Order article via Infotrieve]
13. Schischmanoff, P. O., Yaswen, P., Parra, M. K., Lee, G., Chasis, J. A., Mohandas, N., and Conboy, J. G. (1997) J. Biol. Chem. 272, 10254-10259[Abstract/Free Full Text]
14. Cohen, C. M., Foley, S. F., and Korsgren, C. (1982) Nature 299, 648-650[CrossRef][Medline] [Order article via Infotrieve]
15. Correas, I. (1991) Biochem. J. 279, 581-585[Medline] [Order article via Infotrieve]
16. De Cárcer, G., Lallena, M. J., and Correas, I. (1995) Biochem. J. 312, 871-877[Medline] [Order article via Infotrieve]
17. Krauss, S. W., Larabell, C. A., Lockett, S., Gascard, P., Penman, S., Mohandas, N., and Chasis, J. A. (1997) J. Cell Biol. 137, 275-289[Abstract/Free Full Text]
18. Krauss, S. W., Chasis, J. A., Rogers, C., Mohandas, N., Krockmalnic, G., and Penman, S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7297-7302[Abstract/Free Full Text]
19. Lallena, M. J., and Correas, I. (1997) J. Cell Sci. 110, 239-247[Abstract/Free Full Text]
20. Leto, T. L., Pratt, B. M., and Madri, J. A. (1986) J. Cell. Physiol. 127, 423-431[Medline] [Order article via Infotrieve]
21. Cohen, A. R., Woods, D. F., Marfatia, S. M., Walther, Z., Chishti, A. H., Anderson, J. M., and Wood, D. F. (1998) J. Cell Biol. 142, 129-138[Abstract/Free Full Text]
22. Lallena, M. J., Martínez, C., Valcárcel, J., and Correas, I. (1998) J. Cell Sci. 111, 1963-1971[Abstract/Free Full Text]
23. Nunomura, W., Takakuwa, Y., Tokimitsu, R., Krauss, S. W., Kawashima, M., and Mohandas, N. (1997) J. Biol. Chem. 272, 30322-30328[Abstract/Free Full Text]
24. Mattagajasingh, S. N., Huang, S. C., Hartenstein, J. S., and Benz, E. J., Jr. (2000) J. Biol. Chem. 275, 30573-30585[Abstract/Free Full Text]
25. Kontrogianni-Konstantopoulos, A., Huang, S. C., and Benz, E. J., Jr. (2000) Mol. Biol. Cell 11, 3805-3817[Abstract/Free Full Text]
26. Kontrogianni-Konstantopoulos, A., Frye, C. S., Benz, E. J., Jr., and Huang, S. C. (2001) J. Biol. Chem. 276, 20679-20687[Abstract/Free Full Text]
27. Hou, C. L., Tang, C., Roffler, S. R., and Tang, T. K. (2000) Blood 96, 747-753[Abstract/Free Full Text]
28. Tang, C. J., and Tang, T. K. (1998) Blood 92, 1442-1447[Abstract/Free Full Text]
29. Pu, W. T., Krapivinsky, G. B., Krapivinsky, L., and Clapham, D. E. (1999) Mol. Cell. Biol. 19, 4113-4120[Abstract/Free Full Text]
30. Perez-Ferreiro, C. M., Luque, C. M., and Correas, I. (2001) J. Biol. Chem. 276, 44785-44791[Abstract/Free Full Text]
31. Hung, L. Y., Tang, C. J., and Tang, T. K. (2000) Mol. Cell. Biol. 20, 7813-7825[Abstract/Free Full Text]
32. Mattagajasingh, S. N., Huang, S. C., Hartenstein, J. S., Snyder, M., Marchesi, V. T., and Benz, E. J. (1999) J. Cell Biol. 145, 29-43[Abstract/Free Full Text]
33. Luque, C. M., Lallena, M. J., Alonso, M. A., and Correas, I. (1998) J. Biol. Chem. 273, 11643-11649[Abstract/Free Full Text]
34. Luque, C. M., and Correas, I. (2000) J. Cell Sci. 113, 2485-2495[Abstract/Free Full Text]
35. Gascard, P., Lee, G., Coulombel, L., Auffray, I., Lum, M., Parra, M., Conboy, J. G., Mohandas, N., and Chasis, J. A. (1998) Blood 92, 4404-4414[Abstract/Free Full Text]
36. Gascard, P., Nunomura, W., Lee, G., Walensky, L. D., Krauss, S. W., Takakuwa, Y., Chasis, J. A., Mohandas, N., and Conboy, J. G. (1999) Mol. Biol. Cell 10, 1783-1798[Abstract/Free Full Text]
37. Luque, C. M., Lallena, M. J., Pérez-Ferreiro, C. M., de Isidro, Y., De, Cárcer, G., Alonso, M. A., and Correas, I. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 14925-14930[Abstract/Free Full Text]
38. Nigg, E. A. (1997) Nature 386, 779-787[CrossRef][Medline] [Order article via Infotrieve]
39. Görlich, D., and Mattaj, I. W. (1996) Science 271, 1513-1518[Abstract]
40. Yoneda, Y. (2000) Genes Cells 5, 777-787[Abstract/Free Full Text]
41. Toyoshima, F., Moriguchi, T., Wada, A., Fukuda, M., and Nishida, E. (1998) EMBO J. 17, 2728-2735[Abstract/Free Full Text]
42. Wen, W., Meinkoth, J. L., Tsien, R. Y., and Taylor, S. S. (1995) Cell 82, 463-473[Medline] [Order article via Infotrieve]
43. Fukuda, M., Gotoh, I., Gotoh, Y., and Nishida, E. (1996) J. Biol. Chem. 271, 20024-20028[Abstract/Free Full Text]
44. Fischer, U., Huber, J., Boelens, W. C., Mattaj, I. W., and Luhrmann, R. (1995) Cell 82, 475-483[Medline] [Order article via Infotrieve]
45. Englmeier, L., Olivo, J. C., and Mattaj, I. W. (1999) Curr. Biol. 9, 30-41[CrossRef][Medline] [Order article via Infotrieve]
46. Evan, G. I., Lewis, G. K., Ramsay, G., and Bishop, J. M. (1985) Mol. Cell. Biol. 5, 3610-3616[Medline] [Order article via Infotrieve]
47. Smith, D. B., and Johnson, K. S. (1988) Gene (Amst.) 67, 31-40[CrossRef][Medline] [Order article via Infotrieve]
48. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
49. Englmeier, L., Fornerod, M., Bischoff, F. R., Petosa, C., Mattaj, I. W., and Kutay, U. (2001) EMBO Rep. 2, 926-932[Abstract/Free Full Text]
50. Wada, A., Fukuda, M., Mishima, M., and Nishida, E. (1998) EMBO J. 17, 1635-1641[Abstract/Free Full Text]
51. Kim, F. J., Beeche, A. A., Hunter, J. J., Chin, D. J., and Hope, T. J. (1996) Mol. Cell. Biol. 16, 5147-5155[Abstract]
52. Bogerd, H. P., Fridell, R. A., Benson, R. E., Hua, J., and Cullen, B. R. (1996) Mol. Cell. Biol. 16, 4207-4214[Abstract]
53. Han, B. G., Nunomura, W., Takakuwa, Y., Mohandas, N., and Jap, B. K. (2000) Nat. Struct. Biol. 7, 871-875[CrossRef][Medline] [Order article via Infotrieve]
54. Jacobs, M. D., and Harrison, S. C. (1998) Cell 95, 749-758[Medline] [Order article via Infotrieve]
55. Mittl, P. R., Chene, P., and Grutter, M. G. (1998) Acta Crystallogr. Sect. D Biol. Crystallogr. 54, 86-89[CrossRef][Medline] [Order article via Infotrieve]
56. Guerois, R., Nielsen, J. E., and Serrano, L. (2002) J. Mol. Biol. 320, 369-387[CrossRef][Medline] [Order article via Infotrieve]
57. Jöns, T., and Drenckhahn, D. (1992) EMBO J. 11, 2863-2867[Abstract]
58. Koffa, M. D., Clements, J. B., Izaurralde, E., Wadd, S., Wilson, S. A., Mattaj, I. W., and Kuersten, S. (2001) EMBO J. 20, 5769-5778[Abstract/Free Full Text]
59. Lin, S. Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., and Hung, M. C. (2001) Nat. Cell Biol. 3, 802-808[CrossRef][Medline] [Order article via Infotrieve]
60. Gonzalez-Mariscal, L., Betanzos, A., and Avila-Flores, A. (2000) Semin. Cell Dev. Biol. 11, 315-324[CrossRef][Medline] [Order article via Infotrieve]
61. Vecchi, M., Polo, S., Poupon, V., van de Loo, J. W., Benmerah, A., and Di Fiore, P. P. (2001) J. Cell Biol. 153, 1511-1517[Abstract/Free Full Text]
62. Bredt, D. S. (2000) Nature 404, 241-242[CrossRef][Medline] [Order article via Infotrieve]
63. Gama-Carvalho, M., Carvalho, M. P., Kehlenbach, A., Valcarcel, J., and Carmo-Fonseca, M. (2001) J. Biol. Chem. 276, 13104-13112[Abstract/Free Full Text]
64. Nakielny, S., and Dreyfuss, G. (1999) Cell 99, 677-690[Medline] [Order article via Infotrieve]
65. Huang, J. P., Tang, C. J., Kou, G. H., Marchesi, V. T., Benz, E. J., Jr., and Tang, T. K. (1993) J. Biol. Chem. 268, 3758-3766[Abstract/Free Full Text]
66. Thompson, J. D., Gibson, T. J., Plewniak, F., Jeanmougin, F., and Higgins, D. G. (1997) Nucleic Acids Res. 25, 4876-4882[Abstract/Free Full Text]
67. Guex, N., and Peitsch, M. C. (1997) Electrophoresis 18, 2714-2723[Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.